Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 3/20 | 0.38 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.38 |
| ▸ | MICA | Q29983 | 1/20 | 0.38 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25340771 | 0.88 | SLC6A2 (0.38) | TOP1KLRK1MICARAET1LSLC6A2 | |
| SCHEMBL25341313 | 0.85 | TOP1 (0.36) | TOP1KLRK1MICARAET1LSLC6A2 | |
| SCHEMBL25341521 | 0.77 | FFAR4 (0.38) | TOP1KLRK1MICARAET1LGRM5 | |
| SCHEMBL25374988 | 0.77 | ADORA2A (0.44) | TOP1GRM5KIF11SMN1; SMN2ALDH1A1 | |
| SCHEMBL25975846 | 0.75 | TOP1 (0.38) | TOP1KLRK1MICARAET1LSLC6A2 | |
| SCHEMBL25379007 | 0.75 | GPBAR1 (0.44) | SMN1; SMN2 | |
| SCHEMBL25376949 | 0.75 | GRM5 (0.39) | TOP1SLC6A2SLC6A4GRM5TRPV1 | |
| SCHEMBL25379729 | 0.75 | GRM5 (0.37) | TOP1SLC6A2SLC6A4GRM5SMN1; SMN2 | |
| SCHEMBL25428400 | 0.74 | PTGIR (0.36) | TOP1KLRK1MICARAET1LGRM5 | |
| SCHEMBL20394412 | 0.74 | GPBAR1 (0.43) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146513-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146513-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |